Search research articles
Contact Us
Filters
Showing results (191-200 of 248) with videos related to
Page
of 25
Sort By:
Cells
|
April 30, 2021
Lysine 53 Acetylation of Cytochrome <i>c</i> in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis
Viktoriia Bazylianska, Hasini A Kalpage, Junmei Wan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
John A Thompson, Robert J Motzer, Ana M Molina, et al.
Cancers
|
May 25, 2024
Characterization of <i>FOLH1</i> Expression in Renal Cell Carcinoma
Eric Ovruchesky, Elizabeth Pan, Melis Guer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers
Emmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
European Urology Oncology
|
August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer
Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancer Research
|
November 12, 2024
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer
Tae Hyun Bae, Ki Woon Sung, Tri M Pham, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 248) with videos related to
Sort By:
Page
of 25
Cells
|
April 30, 2021
Lysine 53 Acetylation of Cytochrome <i>c</i> in Prostate Cancer: Warburg Metabolism and Evasion of Apoptosis
Viktoriia Bazylianska, Hasini A Kalpage, Junmei Wan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
John A Thompson, Robert J Motzer, Ana M Molina, et al.
Cancers
|
May 25, 2024
Characterization of <i>FOLH1</i> Expression in Renal Cell Carcinoma
Eric Ovruchesky, Elizabeth Pan, Melis Guer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers
Emmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Prostate Cancer and Prostatic Diseases
|
January 21, 2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
H H Cheng, R Gulati, A Azad, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
European Urology Oncology
|
August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer
Miguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancer Research
|
November 12, 2024
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer
Tae Hyun Bae, Ki Woon Sung, Tri M Pham, et al.
Page
of 25